Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A 403 Forbidden page appears, replacing the study details and related sections with an error screen, making the record inaccessible to users.
    Difference
    19%
    Check dated 2026-09-20T19:51:47.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.5 to v3.6.6. This indicates a new build/version of the page.
    Difference
    0.1%
    Check dated 2026-08-30T21:41:13.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page's revision metadata was updated from v3.6.4 to v3.6.5, indicating a minor update to the page's revision number.
    Difference
    0.1%
    Check dated 2026-08-09T08:53:42.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The page revision tag was updated to v3.6.4, indicating a minor update to the ClinicalTrials.gov record. No study data or criteria appear to be altered.
    Difference
    0.1%
    Check dated 2026-07-25T18:15:34.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The study's recruitment status was updated to 'Active, not recruiting' with a note that no participants are being sought, indicating enrollment has closed. Several investigator and contact details were removed, reducing publicly listed study contacts.
    Difference
    4%
    Check dated 2026-07-11T14:29:21.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    The page revision label updated from v3.6.2 to v3.6.3, indicating a new version of the page or its underlying system. This update does not alter the study details or other content presented.
    Difference
    0.0%
    Check dated 2026-07-04T08:21:06.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.